The promise of cancer precision medicine hinges on one key concept: target the right disease with the right treatment for the right patient at the right time.
But getting everything right is easier said than done. Today, pathologists face enormous time pressure and have to examine a staggering amount of information to make treatment decisions, for every single cancer patient. QCI Precision Insights simplifies the process. A professional clinical interpretation service that translates molecular data specific to each patient into clinical insights and therapeutic options, QCI Precision Insights delivers the evidence you need within minutes.
With QCI Precision Insights, you can reduce test turnaround time by 85-90%—regardless of panel size.
Powered by a world-class team of molecular biologists and oncologists, QCI Precision Insights delivers concise clinical evidence for each biomarker in the context of the cancer sub-type, listing information on the mutation’s molecular characteristics, roles in disease, and therapeutic, prognostic, and diagnostic implications.
You receive a ready to use expert-assembled report content with detailed assessments of variants, written summaries of evidence with references, treatments, and geographically matched clinical trials.
QIAGEN's professional variant interpretation service utilizes the 4-tiered, evidence-based system as outlined by Li et al. (2017) to categorize somatic sequence variations based on their levels of evidence. To provide granular stratification, our classification system includes additional subcategories and intermediate categories.
In our new technical note, we define and provide examples for the tiers and levels of evidence utilized by QCI Precision Insights.
In this application note, we discuss the importance of streamlined clinical NGS workflows within the hematologic-oncology space. Learn how to develop a robust, automated, and streamlined NGS analysis pipeline for the interpretation and reporting of genomic alterations associated with hematological malignancies.
Hear from Dr. Frederick Racke, Medical Director of Hematology, Oncology & Coagulation at Nichols Institute in San Juan Capistrano, CA, as he discusses the LeukoVantage assay and QCI Precision Insights.
To accelerate test turnaround times and ensure accurate reporting, Quest Diagnostics uses QCI Precision Insights to provide expert interpretation for their LeukoVantage assay, a NGS test for hematologic malignancies. Find out how QCI Precision Insights delivers reports that include diagnostic and prognostic information, therapeutic options, and clinical trials based on the unique combination of genomic alterations detected in each case and WHO, NCCN, and ELN guidelines.
Request a free, no-obligation consultation with a QCI Precision Insights expert to learn more about the service. Start sending us your clinical NGS data today.
